69%) from rural community had feature if depressive illness. Conclusion: Depressive illness is common among patients presenting with gastrointestinal see more symptoms. Lower educational and economic background, female sex, married, housewives and age 25-35 years and >45 years are important associated factors. Key Word(s): 1. gastrointestinal symptoms;

2. depressive illness Presenting Author: ENNALIZA SALAZAR Additional Authors: WAN CHENG CHOW, JASON CHANG Corresponding Author: JASON PIK EU CHANG Affiliations: Singapore General Hospital, Singapore General Hospital Objective: The clinical utility of serial liver stiffness measurements (LSM) for assessment of regression or progression of fibrosis in patients with chronic liver disease (CLD) has not been well established. The aim of this study was to examine the change in fibrosis grade

in CLD patients undergoing serial LSM for longitudinal assessment of liver fibrosis. Methods: Retrospective analysis of 268 patients who underwent repeat LSM for assessment of liver fibrosis in our center between DNA Damage inhibitor 2005-2012. Demographic, clinical and LSM data were analyzed to evaluate for change in fibrosis grade between the first two consecutive LSM measurements. Results: Mean age was 49.7 ± 12.2 years with 67.2% males. Etiology of CLD was chronic hepatitis B (CHB) Flavopiridol (Alvocidib) in 63.8%, chronic hepatitis C (CHC) in 15.3% and non-alcoholic steatohepatitis (NASH) in 20.9%. 243 patients had valid repeat LSMs with

failure of at least one LSM reading in 25 (9.3%). Mean duration between the baseline and repeat LSM was 18.6 ± 12.8 months. A difference in fibrosis grade between the two LSM readings was observed in 151/243 (62.1%), of which 81/243 (30.2%) demonstrated evidence of fibrosis regression whereas 70/243 (26.1%) demonstrated evidence of fibrosis progression on repeat LSM. There was no significant difference in the proportion of fibrosis regression amongst the different etiologies. 138 (56.8%) of the cohort received treatment for their underlying liver disease. However, we did not observe any significant increase in fibrosis regression among treated patients compared with untreated patients (32.8% vs. 34.2%, p = NS), even when stratified by specific etiology. A difference in fibrosis grade was observed more frequently in subjects with repeat LSM within 2 years compared to those with repeat LSM>2 years (66% vs. 50%, p = 0.025). Conclusion: Serial LSM is a useful modality to monitor longitudinal change in liver fibrosis in patients with chronic liver disease. The optimal duration for repeat LSM assessment to demonstrate difference in fibrosis grade should be 2 years. Key Word(s): 1. liver stiffness measurement; 2. fibrosis grade; 3.